.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: RE43390

« Back to Dashboard
Patent RE43390 protects ALTABAX and is included in one NDA.

This patent has forty-nine patent family members in thirty-five countries.

Summary for Patent: RE43390

Title:Pleuromutilin derivatives as antimicrobials
Abstract: The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
Inventor(s): Berry; Valerie Joan (Chester Springs, PA), Dabbs; Steven (Harlow, GB), Frydrych; Colin Henry (Sawbridgeworth, GB), Hunt; Eric (Great Dunmow, GB), Sanderson; Francis Dominic (Harlow, GB), Woodnutt; Gary (Chester Springs, PA)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA) SmithKline Beecham Limited (Brentford, Middlesex, GB)
Application Number:13/102,156
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Aqua Pharms Llc
ALTABAX
retapamulin
OINTMENT;TOPICAL022055-001Apr 12, 2007RXYesRE43390► subscribeYY TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: RE43390

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9722817Oct 29, 1997
United Kingdom9813689Jun 25, 1998
PCT Information
PCT FiledOctober 27, 1998PCT Application Number:PCT/GB98/03211
PCT Publication Date:May 06, 1999PCT Publication Number: WO99/21855

Non-Orange Book Patents for Patent: RE43390

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE39128Pleuromutilin derivatives as antimicrobials► subscribe
6,281,226 Pleuromutilin derivatives as antimicrobials► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: RE43390

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina015987► subscribe
Austria277925► subscribe
Austria525373► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc